Somé Anyirékun Fabrice, Sorgho Hermann, Zongo Issaka, Bazié Thomas, Nikiéma Frédéric, Sawadogo Amadé, Zongo Moussa, Compaoré Yves-Daniel, Ouédraogo Jean-Bosco
Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, 399 Avenue de la liberté, 01 BP 545, Bobo-Dioulasso 01, Burkina Faso.
Institut de Recherche en Sciences de la Santé, Unité de Recherche Clinique de Nanoro, BP 218 Ouaga CMS 11, Burkina Faso.
Parasite. 2016;23:60. doi: 10.1051/parasite/2016069. Epub 2016 Dec 22.
The emergence of resistance to artemisinin derivatives in western Cambodia is threatening to revert the recent advances made toward global malaria control and elimination. Known resistance-mediating polymorphisms in the K13, pfcrt, pfmdr1, pfdhfr, and pfdhps genes are of greatest importance for monitoring the spread of antimalarial drug resistance.
Samples for the present study were collected from 244 patients with uncomplicated malaria in health centers of Bobo-Dioulasso, Burkina Faso. Blood sample was collected on filter paper before the subject received any treatment. The parasite DNA was then extracted and amplified by Polymerase Chain Reaction (PCR) to evaluate the prevalence of polymorphism of pfcrtK76T, pfmdr1 (N86Y, Y184F), and pfdhps (A437G, K540E). The K13 gene polymorphism was analyzed by nested PCR followed by sequencing.
The overall results showed 2.26% (5/221) of K13 synonymous mutant alleles (two C469C, one Y493Y, one G496G, and one V589V), 24.78%, 19.58%, 68.75%, 60.9%, 53.7%, 63.8%, and 64.28%, respectively, for mutant pfcrt 76T, pfmdr1-86Y, pfmdr1-184F, pfdhfr51I, pfdhfr59R, pfdhfr108N, and pfdhps 437G. We did not report any mutation at codon 540 of pfdhps.
These results provide baseline prevalence of known drug resistance polymorphisms and suggest that artemisinin combination therapies may retain good efficacy in the treatment of uncomplicated malaria in Burkina Faso.
柬埔寨西部出现对青蒿素衍生物的耐药性，有可能使全球疟疾控制和消除工作近期取得的进展出现倒退。K13、pfcrt、pfmdr1、pfdhfr和pfdhps基因中已知的耐药性介导多态性对于监测抗疟药物耐药性的传播最为重要。
本研究的样本取自布基纳法索博博迪乌拉索卫生中心的244例非复杂性疟疾患者。在受试者接受任何治疗之前，采集滤纸血样。然后提取寄生虫DNA，并通过聚合酶链反应（PCR）进行扩增，以评估pfcrtK76T、pfmdr1（N86Y、Y184F）和pfdhps（A437G、K540E）多态性的流行情况。通过巢式PCR随后测序分析K13基因多态性。
总体结果显示，K13同义突变等位基因占2.26%（5/221）（两个C469C、一个Y493Y、一个G496G和一个V589V），突变型pfcrt 76T、pfmdr1-86Y、pfmdr1-184F、pfdhfr51I、pfdhfr59R、pfdhfr108N和pfdhps 437G分别占24.78%、19.58%、68.75%、60.9%、53.7%、63.8%和64.28%。我们未报告pfdhps第540位密码子的任何突变。
这些结果提供了已知耐药性多态性的基线流行情况，并表明青蒿素联合疗法在布基纳法索治疗非复杂性疟疾方面可能仍具有良好疗效。
